Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of V540A versus Gardasil 9 in healthy women aged 16-26
MOH_2025-10-22_014395Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V540A and recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (3 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of three-dose V540A regimens and Immunogenicity to HPV types shared with V503. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
V540Arecombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on MOH_2025-10-22_014395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-22_014395.